公开(公告)号：US20210340112A1

公开(公告)日：2021-11-04

申请号：US17365716

申请日：2021-07-01

Applicant: NOVARTIS AG

Inventor： Birgit BOLLBUCK ,  Christian MARKERT ,  Wolfgang MILTZ ,  Till ROEHN

IPC: C07D257/04 ,  C07D231/12 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12 ,  C07D271/10 ,  A61K45/06 ,  A61K31/41 ,  A61K31/415 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/4439

Abstract: The present invention describes novel heteroaryl butanoic acid derivatives that are good drug candidates especially with regard to leukotriene A4 hydrolase (LTA4H). The present invention also relates to pharmaceutical compositions comprising said novel heteroaryl butanoic acid derivatives, methods of using said compounds in the treatment of various diseases and disorders, and processes for preparing the said novel compounds.

公开(公告)号：US20240043425A1

公开(公告)日：2024-02-08

申请号：US18319585

申请日：2023-05-18

Applicant: NOVARTIS AG

Inventor： Mallesh BUSHABOINA ,  Xin CHEN ,  Atwood Kim CHEUNG ,  Andrew James CULSHAW ,  Timothy Brian HURLEY ,  Nancy LABBE-GIGUERE ,  Wolfgang MILTZ ,  David ORAIN ,  Tajesh PATEL ,  Srinivasan RAJAGOPALAN ,  Till ROEHN ,  David Andrew SANDHAM ,  Gebhard THOMA ,  Ritesh Bhanudasji TICHKULE ,  Rudolf WÄLCHLI

IPC: C07D471/10 ,  A61K45/06 ,  C07D519/00

CPC classification number: C07D471/10 ,  C07D519/00 ,  A61K45/06

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;






wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20180170887A1

公开(公告)日：2018-06-21

申请号：US15895224

申请日：2018-02-13

Applicant: NOVARTIS AG

Inventor： Birgit BOLLBUCK ,  Christian MARKERT ,  Wolfgang MILTZ ,  Till ROEHN

IPC: C07D257/04 ,  A61K31/4439 ,  A61K31/41 ,  A61K31/415 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/428 ,  A61K45/06 ,  C07D417/12 ,  C07D413/12 ,  C07D401/12 ,  C07D231/12 ,  C07D271/10

CPC classification number: C07D257/04 ,  A61K31/41 ,  A61K31/415 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/4439 ,  A61K45/06 ,  C07D231/12 ,  C07D271/10 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12

Abstract: The present invention describes novel heteroaryl butanoic acid derivatives that are good drug candidates especially with regard to leukotriene A4 hydrolase (LTA4H). The present invention also relates to pharmaceutical compositions comprising said novel heteroaryl butanoic acid derivatives, methods of using said compounds in the treatment of various diseases and disorders, and processes for preparing the said novel compounds.

公开(公告)号：US20250092042A1

公开(公告)日：2025-03-20

申请号：US18924066

申请日：2024-10-23

Applicant: NOVARTIS AG

Inventor： Mallesh BUSHABOINA ,  Xin CHEN ,  Atwood Kim CHEUNG ,  Andrew James CULSHAW ,  Timothy Brian HURLEY ,  Nancy LABBE-GIGUERE ,  Wolfgang MILTZ ,  David ORAIN ,  Tajesh PATEL ,  Srinivasan RAJAGOPALAN ,  Till ROEHN ,  David Andrew SANDHAM ,  Gebhard THOMA ,  Ritesh Bhanudasji TICHKULE ,  Rudolf WÄLCHLI

IPC: C07D471/10 ,  A61K45/06 ,  C07D519/00

Abstract: The present invention provides a method for manufacturing a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein R1 R2, R4 and X1 are defined herein.

公开(公告)号：US20220411385A1

公开(公告)日：2022-12-29

申请号：US17820348

申请日：2022-08-17

Applicant: NOVARTIS AG

Inventor： Birgit BOLLBUCK ,  Christian MARKERT ,  Wolfgang MILTZ ,  Till ROEHN

IPC: C07D257/04 ,  C07D231/12 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12 ,  C07D271/10 ,  A61K45/06 ,  A61K31/41 ,  A61K31/415 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/4439

Abstract: The present invention describes novel heteroaryl butanoic acid derivatives that are good drug candidates especially with regard to leukotriene A4 hydrolase (LTA4H). The present invention also relates to pharmaceutical compositions comprising said novel heteroaryl butanoic acid derivatives, methods of using said compounds in the treatment of various diseases and disorders, and processes for preparing the said novel compounds.